Introduction N-acetyl-L-cysteine (NAC) is a thiol antioxidant that is commonly used as a mycolytic agent. NAC stimulates glutathione synthesis and scavenges free radicals and is used as an antidote for an overdose of paracetamol hepatotoxicity.
1,2 Proliferation of NIH 3T3 fibroblast cells is suppressed by NAC, and this antiproliferative effect is mediated by reversal blocking of cell cycle progression in G 1 phase. 3, 4 By blocking protein kinases, NAC may reduce cell death mediated by oxidative stress. 5 These effects by NAC inspired us to use it to treat veno-occlusive disease of the liver (VOD) and to treat patients with liver toxicity during busulfan conditioning for allogeneic hematopoietic stem cell transplantation (ASCT). 6, 7 Liver toxicity is common after ASCT and its conditioning with high-dose chemoradiotherapy. 8 The most severe form of liver toxicity after ASCT is hepatic VOD with an incidence of 10-70%. [9] [10] [11] [12] Endothelial cell damage and activation of clotting factors and cytokines are early events of VOD. [13] [14] [15] [16] We wanted to evaluate the efficacy of NAC to improve liver toxicity and possibly prevent VOD. An open-labeled prospective randomized study was performed treating patients with early liver dysfunction with NAC or no treatment early after ASCT.
Materials and methods

Inclusion criteria
Patients with elevated bilirubin 426 mmol/l and/or conjugated bilirubin 48 mmol/l, and/or increased levels of alanine aminotransferase (ALT) 41.4 mkat/l (normal value o0.7) or aspartate aminotransferase (AST) 41.4 mkat/l (normally o0.7) from conditioning until day þ 21, were randomized to be treated with Acetylcystein (NAC, AstraZeneca, So¨derta¨lje, Sweden), or not (control group). Patients were randomized without stratification regardless of reason for early liver toxicity. Randomization was performed in cohorts of 20 in each group. NAC 100 mg/kg bodyweight was given as a continuous 6-h infusion. If toxicity appeared during pretransplant conditioning, NAC was given as a 3-h infusion starting 6 h after the previous busulfan (BU) dose and ending 3 h before the subsequent dose, based on a previous pilot study. 7 Treatment with NAC was not given within 12 h before or after CY treatment. The primary end point was maximum bilirubin. The treatment was continued until elevated bilirubin and/or transaminases normalized. Treatment was also discontinued if the patient was discharged from the hospital even with slightly elevated liver tests.
The study was approved by the Ethics Committee at Huddinge University Hospital and was performed according to the Declaration of Helsinki. All patients included in the study gave informed consent.
Patients
Between October 1999 and February 2007, 522 consecutive patients received ASCT at our unit. Among those, 160 (31%) fulfilled the inclusion criteria and were randomized to NAC or not. Patient characteristics are given in Table 1 . There were significantly more patients with nonmalignant disorders among the controls (P ¼ 0.003). Follow-up was a median of 40 (1.3-79) months.
Donors and tissue typing
The donors were HLA-identical siblings, matched unrelated donors (HLA-A, -B and -DRb1 genomically matched) or HLA-mismatched related or unrelated (Table 1) . HLA-typing was genomic for HLA class I and II. 17 Stem cell sources were bone marrow, granulocyte colony stimulating factor-mobilised peripheral blood stem cells or cord blood cells (Table 1) .
18 CD34 cell dose median was 8.5 Â 10 6 per kg in the NAC group, which was significantly higher, as compared to 6.7 Â 10 6 per kg in the controls (Table 1 , P ¼ 0.01).
Conditioning CY, 120 mg/kg, was combined with fractionated TBI, 3 Gy per day Â 4 days, in patients with hematological malignancies. BU, 16 mg/kg, was combined with CY, 120 mg/kg, in patients who had hematological malignancies and CY 8 g/m 2 in patients with inborn error of metabolism. 19, 20 Reduced intensity conditioning (RIC) consisted of fludarabine (30 mg/m 2 per day) for 5-6 days, combined with BU, 8 mg/kg, or CY, 120 mg/kg. 21, 22 Some patients with solid tumors and multiple myeloma were treated with fludarabine, 30 mg/m 2 per day for 3 consecutive days, followed by 2 Gy TBI. 21, 23 Patients with nonmalignant disorders or with an unrelated donor, regardless of disease, were treated with anti-T-cell globulin (ATG). 24 Therapeutic drug monitoring from the first dose was applied to all patients treated with BU followed by adjustment for patients with higher AUC than 5000 ng/h per ml.
Graft-versus-host disease prophylaxis
As prophylaxis against GVHD, CsA was combined with a short course of methotrexate in most patients. 25, 26 Supportive care Most patients were treated in reversed isolation, some were treated at home. 27 G-CSF, 5 mg/kg per day i.v., was given from day þ 10 and until ANC were 40.5 Â 10 9 per liter for 2 days to enhance engraftment. This routine was discontinued when it was found that in our unit, G-CSF increased the risk of acute GVHD. 28 Acyclovir prophylaxis was given to patients with a high herpes simplex virus titer. 29 Details regarding supportive care were previously published in detail. 25, 27 All patients were treated with ursodiol, 12 mg/kg per day, to prevent liver toxicity. 8 Liver toxicity, definitions and statistics VOD was diagnosed according to the criteria stated by Jones et al.;
10 an onset before day 21 of hyperbilirubinemia and two of the following, weight gain 45%, tender hepatomegaly and ascites. 
Analysis was performed on 20 March 2007. The probabilities of overall survival and relapse-free survival were estimated using the method of Kaplan-Meier and compared with the log-rank test. 30 The incidence of GVHD, transplant-related mortality (TRM) and relapse was estimated nonparametrically. Patients were censored at the time of death, relapse or last follow-up. Relapse and nonrelapse mortality are competing events. Their incidence rates were therefore estimated using a nonparametric estimator of cumulative incidence curves. 31 Predictive analyses for GVHD and TRM were based on the proportional hazard model for subdistribution of competing risk. Univariate and multivariate analyses were then performed using Gray's test and the proportional subdistribution hazard regression model of Fine and Gray. A stepwise backward procedure was used to construct a set of independent predictors for each end point. All predictors with a P-value o0.10 were considered, and sequentially removed if the P-value in the multiple model was 40.05. All tests were two-sided. The type I error rate was fixed at 0.05 for factors potentially associated with time-to-event outcomes. Factors analyzed in the univariate analysis: patient and donor sex and age, sex-mismatch, diagnose, disease stage, type of donor, ATG, previous HSCT, conditioning (BU versus TBI based and RIC versus conventional), stem-cell source, G-CSF, home care, CMV serology, nucleated and CD34 þ cell-dose and GVHD. Analyses were performed using the cmprsk package (developed by Gray, June 2001), Splus 6.2 software and Statistica software. The Mann-Whitney U-test was used to compare continuous variables and the w 2 method was used to compare the distribution of categorical variables.
Results
Treatment with acetylcysteine
Out of 160 patients included in the study, 72 were randomized to treatment with NAC because of signs of liver toxicity. Patients were treated for a median of 15 (range 4-89) days. There was no infusion-related toxicity or side effects by this treatment. One patient in the acetylcysteine group complained of high amounts of mucus being disturbing, especially at night.
Engraftment, transfusions and infections
Time to ANC 40.5 Â 10 9 per liter was a median of 17 days in both groups. To reach platelets 430 Â 10 9 per liter was median 16 days in the NAC group and 15 days in the controls (NS). Patients treated with NAC required slightly more erythrocyte transfusions (range 0-44), as compared to the controls (0-26, P ¼ 0.09), but need of platelet transfusions was similar in the two groups (NS). Graft failure was diagnosed in 6 (8%) in the NAC-treated patients and 8 (9%) in the controls (NS).
The incidence of bacteremia was 43% in the NAC group and 35% in the controls (NS). CMV infection diagnosed as PCR DNA positivity was observed in 48 (66%) in the NAC group, as compared to 43 (49%) in the controls (P ¼ 0.05). CMV disease was 9 (13%) and 7 (8%) in the two groups, respectively.
Liver toxicity
Bilirubin levels preconditioning, prerandomization, maximum levels during the study and 1 month after inclusion were the same in patients treated with NAC and the controls (Figure 1a) . Maximum ALT levels during the study period were not significantly different between the NAC-treated patients and the controls (Figure 1b) . The curves regarding ALT and AST in the NAC group and the controls followed each other (Figures 1b and c) . At randomization and 1 month after inclusion in the study, ALT levels were significantly higher in the NAC group, as compared to the controls (Figure 1b, Po0.05) . When we analyzed patients receiving BU conditioning, myeloablative conditioning and RIC separately, maximum bilirubin, ALT and AST and recovery were the same in the NAC groups and the controls. For instance, when we analyzed patients conditioned with BU separately, maximum bilirubin was median 30 (range 12-442) mmol/l in the NAC group, as compared to 28 (7-394) mmol/l in the controls. Among patients receiving myeloablative conditioning, maximum bilirubin was median 38 (range 13-442) mmol/l in the NAC group, as compared to 30 (7-503) mmol/l in the controls (NS). The corresponding figures for patients with RIC was 31 (5-191 mmol/l) and 29 ) mmol/l in the two groups, respectively (NS).
There were two patients who developed VOD in the NAC group and three patients among the controls. Conditioning in the five patients who developed VOD was BU/CY in three, CY and TBI in one and RIC in one.
GVHD and transplant-related mortality
Patients without acute GVHD were 30 (41%) in the NAC group versus 37 (43%) in the controls. Acute GVHD grade III-IV was seen in 6 (8%) in the NAC group, as compared to 12 (14%) in the controls. The cumulative incidence of chronic GVHD did not differ between the NAC group (26%) and the controls (28%).
TRM at 100 days was 18% in the NAC group, as compared to 6% in the controls. In multivariate analysis, TRM was significantly associated with acute GVHD grades II-IV (Po0.001) and retransplantation (P ¼ 0.016).
Relapse and survival The probability of relapse among patients with malignant disorders was 23% at 4 years in the NAC group (n ¼ 58), as compared to 29% in the controls (n ¼ 64, NS). The 4-year probability of survival all patients included was 49% in the NAC group and 62% in the controls (Figure 2a , P ¼ 0.09). Relapse-free survival was the same in the two groups (Figure 2b) . In multivariate analysis, death was associated with acute GVHD grades II-IV, G-CSF prophylaxis (relative hazard (RH) 1.8, P ¼ 0.03) and malignant diseases (RH 0.11, P ¼ 0.03). If GVHD was excluded, BU conditioning (RH 0.47, P ¼ 0.003), nonmalignant diseases (RH 0.06, P ¼ 0.007) and home care (RH 0.29, P ¼ 0.03) were significantly correlated to a decreased risk of death.
Discussion
Because NAC has antioxidant effects and may reduce cell death mediated by oxidative stress, we used it for treatment of VOD. [3] [4] [5] Three patients with VOD recovered during NAC treatment. 6 Subsequently, we used NAC in patients who developed liver toxicity during BU therapy. 7 These studies inspired us to do the present prospective randomized study. NAC has also been used together with ASCT as an antioxidant agent to protect from neurologic decline in boys with adrenoleukodystrophy. 32 A study in rats proposed that support of sinusoidal endothelial cell glutathione prevented the development of hepatic VOD and NAC preserved glutathione in liver cell homogenates. 33 Thus, there were suggestions that NAC may be useful to heal or prevent hepatotoxicity after ASCT.
In spite of the low frequency of VOD, this study may suggest that NAC did not prevent VOD, when given for early toxicity. Furthermore, maximum bilirubin levels were the same in the two groups. ALT and AST values were significantly or tended to be higher at the time of inclusion in the NAC group, as compared to the controls, that probably is due to coincidence. The maximum values and decline of these liver enzymes did not differ in the NAC group and the controls. Therefore, it can be concluded from this study that NAC given as early therapy does not prevent the development of more severe liver toxicity. Our findings may not be in contrast to the rat study. 33 It showed that glutathione rescue had a highly variable effect, from complete protection to complete lack of protection. That study only included five animals. NAC protected monocrotaline induced liver toxicity in three animals. That study did not include NAC therapy for early toxicity. Whether prophylactic NAC will protect for liver toxicity in ASCT remains an open question. The overall incidence of VOD was low in the patients in both groups, 3%. This is low as compared to the reports in the literature, being between 10 and 70% in different materials. [9] [10] [11] [12] 16 One reason for this may be that all patients received ursodiol, which proved effective to prevent liver toxicity and improved survival after ASCT. 8 We previously reported that norethisterone treatment was a major risk factor for VOD in women, resulting in a 30% incidence. 34 Since we stopped using norethisterone to prevent menstruation during the pancytopenic period, the incidence of VOD decreased among our ASCT patients. One more reason that might explain the low incidence of VOD in our material is the introduction of therapeutic drug monitoring and the dose adjustment of BU. 35 The use of RIC in elder and high-risk patients probably also have contributed to the low probability of VOD. [21] [22] [23] Slavin et al. 22 reported four cases of VOD after RIC. One patient in the present study developed VOD after RIC.
The two groups were comparable with regard to most characteristics that may affect liver toxicity after transplant. Due to no stratification and chance, there were significantly more patients with nonmalignant disorders in the control group (Table 1) . Patients with nonmalignant disorders had a better outcome after ASCT than patients with malignant disorders. The NAC group had a statistically higher CD34 cell dose, as compared to the controls. A high CD34 cell dose was reported to be associated with a decreased relapse risk and a low CD34 dose was reported to be associated with an increased TRM. 36 Despite this, the control group had a trend for a better TRM, as compared to the NAC group (P ¼ 0.08). An additional reason may be more CMV infections, 66 versus 49% in the controls. CMV infection is associated with delayed immune reconstitution and other infections, which may have affected TRM in these patients. 37, 38 Relapse and relapse-free survival was the same in the NAC group and the controls (Figure 2) . Therefore, the trend for a better survival in the controls as compared to the NAC patients overall is due to the higher number of patients with nonmalignant disorders in the control group. G-CSF prophylaxis was associated with an increased risk of death and home-care patients had improved survival in keeping with previous reports. 27, 28, 39 A prophylaxis study of NAC was not carried out, but NAC was introduced at first sign of liver toxicity with no effect on liver toxicity. We have stopped using NAC as treatment for liver toxicity and VOD. It can be concluded from this randomized trial that early treatment with NAC does not prevent progression of liver toxicity after ASCT.
